PTO/SB/08b (04-09)

Approved for use through 05/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

for form 1449/PTO

Sheet

1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

1

Complete if Known			
Application Number	10/752,423		
Filing Date	January 6, 2004		
First Named Inventor	Erik Buntinx		
Art Unit	1617		
Examiner Name	Umamaheswari Ramachandran		
Attorney Docket Number	29248/19		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	STEIN D J et al, entitled "Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders," J Clin Psychiatry, 1997, 58(3):119-122.	
	2	ALBERT U et al., entitled "Management of treatment resistant obsessive-compulsive disorder. Algorithms for Pharmacotherapy," Panminerva Med, 2002, 44(2):83-91.	
	3	Mohr N et al., entitled "Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorders," Int J Psychopharmacol, 2002, 17(1):37-40.	
	4	Silver H, entitled "Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia," 2003, Int Clin Psychopharmacol, 18(6):305-313.	
·			
<u>.</u>			
-			

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to life (and by the OSFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.